Non-Celiac Gluten/Wheat Sensitivity Affects 1 in 10 Globally, Often with Comorbid IBS
One in ten adults report NCGWS, frequently coexisting with IBS, anxiety, or depression, suggesting a central role for the gut-brain axis in pathophysiology.
Brain Changes, Weight Management, and Breast Screening: Essential Updates From TMS 2025
New research from TMS 2025 covers menopause effects on brain volume, hormone therapy's role in weight loss with GLP-1s, and dense breast screening updates.
Atopic Dermatitis Treatment Preferences: Age and Severity Guide Therapy Selection in Youth
Treatment goals for atopic dermatitis among youth are diverse, emphasizing the need for tailored approaches based on age and disease severity, a new study suggests.
7 Drugs Approved for Primary Care: Q3 2025
Catch up on the 7 FDA drug approvals from Q3 2025 most relevant to primary care, including new treatments for cardiometabolic, infectious disease, and inflammatory diseases.
When Should Mammography Begin? Donna Plecha, MD, on Differing Breast Cancer Screening Guidelines
Early breast cancer screening at age 40, especially with 3D mammograms, significantly improves survival rates and quality of life, according to Dr Plecha.
Community Factors Show Distinct Patterns Across Cancer Types in Nationwide Analysis
Smoking drives lung cancer deaths, but race predicts breast/prostate mortality. New study reveals distinct community factors for each cancer type's outcomes.
FAQs On The Critical Window Hypothesis for Menopausal Hormone Therapy's Neuroprotective Effects
Common questions on the critical window hypothesis for timing of postmenopausal MHT ask about rationale, clinical evidence, and guideline response.
MHT and Alzheimer Risk: New Evidence for a Critical Window, with Roksana Karim, MD, PhD
Karim discusses secondary findings from the ELITE trial of timing for estradiol initiation, which reveal a notable impact on Aβ biomarkers of Alzheimer disease.
Why Do Women Suffer in Silence with Genitourinary Syndrome of Menopause?
Menopause specialist Caroline Mitchell, MD, MPH, explains the dual nature of the breakdown in communication that can leave women virtually uninformed about GSM and treatment.
Xuezhi Daniel Jiang, MD, PhD, on Counseling Postmenopausal Women on Autoimmune Disease Risk Without Creating Hormone Therapy Phobia
Jiang shares how to use new autoimmune risk data responsibly—identifying high-risk patients while avoiding unnecessary hormone therapy phobia.
Mazdutide Demonstrates Superior Glycemic Control and Weight Loss vs Semaglutide in Head-to-Head Trial
The phase 3 DREAMS-3 trial is the fist phase 3 head-to-head comparison of a GLP-1/glucagon dual receptor agonist against semaglutide in diabetes treatment.
Hormone Therapy Linked to Increased Autoimmune Disease Risk
Dr. Daniel Jiang shares unexpected research findings showing hormone therapy increased autoimmune disease risk across 15 of 17 conditions in postmenopausal women.
Investigational Oral Agent ALZ-801 Slows Brain Atrophy and Cognitive Decline in APOE4 Homozygotes with Early AD
Valiltramiprosate is a novel disease modifying therapy designed to inhibit formation of soluble neurotoxic amyloid oligomers, acting upstream in the amyloid cascade.
Hormone Therapy and Autoimmune Disease Risk in Postmenopausal Women, With Xuezhi Daniel Jiang, MD, PhD
TMS 2025: Jiang explains why he investigated hormone therapy's effect on autoimmune disease risk in postmenopausal women.
AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial
After 1 year of coaching by the AI app or a DPP-associated coach, reductions in weight and HbA1c and increases in physical activity were equal, an outcome with great promise for scalability.
Estetrol Phase 3 Trial Shows No Impact on Postmenopausal BP, Even in Women at High CV Risk
The phase 3 E4COMFORT II trial found no impact on BP after 1 year of treatment in postmenopausal women with elevated HbA1c, lipids, and TGs.
Caroline Mitchell, MD, Describes Toll of Genitourinary Syndrome of Menopause on QoL
TMS: Half of postmenopausal women suffer from GSM, yet only 25% seek treatment. Mitchell, an expert in vulvovaginal health, explains the gap and its impact on women.
FDA Green-Lights Elinzanetant, First Dual NK-1/NK-3 Antagonist, for Moderate to Severe Vasomotor Symptoms of Menopause
The novel once-daily nonhormonal therapy offers a new option to offer women who prefer not to take HRT or for whom it is contraindicated.
Marla Shapiro, CM, MDCM, on Recognizing Early Perimenopause: Sleep, Mood, and Other Missed Clues
Subtle sleep, mood, and cycle changes may herald perimenopause. Dr. Marla Shapiro discusses how clinicians can recognize and address them early.
Menopause Education Lags in Residency Training Across Primary Care Specialties
Less than one-third of residents in IM, FM, and OB/GYN programs receive structured menopause training, leaving many unprepared for midlife women’s care.
Timing of Menopausal Hormone Therapy May Impact Biomarkers of Alzheimer Disease
A secondary analysis of the ELITE trial suggests that there may be a postmenopausal "critical window" during which use of MHT is optimal.
Menopause Education Wholly Inadequate for Physician Associates, According to New Survey Results
Only 3% of physician associate respondents reported receiving more than 5 hours of menopause-related training during their professional education.
Treating Hot Flashes May Improve Cognitive Symptoms: Study Author Explains the Connection
TMS 2025: Katrina Wugalter, MA, explains why treating vasomotor symptoms may be key to improving cognitive function during menopause.
APOE ε4 and Inflammation Amplify Risk for Memory Decline in Women with Earlier Menopause
Earlier menopause, APOE ε4, and age-related inflammation combine to accelerate memory decline, revealing key factors in women’s Alzheimer disease risk.
Inequities in Menopause Care: How Provider and Patient Factors Combine to Limit Treatment
TMS: Menopause care isn’t one-size-fits-all—and that’s the problem. Wake Forest data reveal deep disparities in who gets treated and how.
Semaglutide CV Effects Appear Independent of Baseline Adiposity, Suggesting Disease-Modifying Potential
In a subanalysis of the SELECT trial, semaglutide was associated with reduction in MACE across weight and waist circumference categories, independent of body fat.
Donna Plecha, MD: Why You Should Start Breast Cancer Risk Assessment at Age 25
TMS 2025: Donna Plecha, MD, an expert in breast imaging, discusses essential breast cancer screening recommendations for primary care physicians.
Topline Real-World Data Show Fezolinetant Improves VMS, Sleep, and Work Productivity in Women With Confirmed Menopausal VMS
TMS: New preliminary data show reduction in bothersome VMS as early as week 4, an effect that led to statistically significant improvements across other life domains.
Four Studies Build Evidence for Elinzanetant as a Safe, Effective Nonhormonal Option for Menopausal Vasomotor Symptoms
TMS: New data pooled across clinical trials confirm elinzanetant’s consistent efficacy, safety, and sleep benefits across diverse populations of menopausal women.
Elinzanetant Improves Sleep Through VMS-Independent Mechanisms, According to New Pooled Analysis
TMS: Mediation analysis found that more than half of elinzanetant's sleep benefit occurs independently of nighttime hot flash reduction, challenging VMS-centric models.
